Open AccessHumoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Author(s) -
Ronit Gurion,
Uri Rozovski,
Gilad Itchaki,
Anat GafterGvili,
Chiya Leibovitch,
Pia Raanani,
Haim BenZvi,
Moran Szwarcwort,
Mor Taylor-Abigadol,
Eldad J. Dann,
Nurit Horesh,
Tsofia Inbar,
Inna Tzoran,
Noa Lavi,
Riva Fineman,
Shimrit Ringelstein-Harlev,
Netanel A. Horowitz
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279216
Subject(s) - medicine , serology , lymphoma , odds ratio , confidence interval , monoclonal antibody , immunology , antibody , vaccination , titer , cd20
Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies (MoAb), suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors impacting the response.Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott©) assay in blood samples drawn from lymphoma patients 4±2 weeks after the 2nd vaccine dose. The cutoff for a positive response was set at 50AU/ml.Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of